# Junta clínica — PT-pseudo_d3e975d025e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d3e975d025e6",
  "pid": "PT-pseudo_d3e975d025e6",
  "task": 1,
  "psa": 15.8,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.318,
  "psav": 0.96,
  "psap": 15.4,
  "vol": 49.63,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.84823215,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "69 kg",
    "height": "179 cm",
    "bmi": "21.5",
    "bp": "127/86 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "18 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results."
    },
    {
      "s": "History",
      "t": "First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly."
    }
  ],
  "occupation": "tram driver",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Vascular surgery — varicose veins consult"
  ],
  "alcohol": "6 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3e975d025e6
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 15.8 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.318 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 15.4 ng/mL
  - Prostate volume: 49.63 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84823215 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 15.8 ng/mL. PI-RADS 5. PSAD 0.32. Prostate volume 50 mL. DRE nodus. csPCa 0.85.

Vitals: weight 69 kg, height 179 cm, BMI 21.5, BP 127/86 mmHg, HR 72 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Ongoing assessment is required for sustained PSA elevation and newly acquired multiparametric MRI results.

History: First evaluated for a January 2023 PSA elevation, this 67-year-old tram driver resides with his married partner and reports zero lower urinary tract symptoms (IPSS score of zero). He maintains an active routine, logging roughly 30 kilometres of cycling three times weekly, alongside a modest alcohol intake of six units per week. Tobacco use ceased in 2016 after a cumulative 19 pack-year exposure. His medical background remains clear, with no comorbidities or active medications documented. Morning scheduling aligns with his public transport needs. He denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Per rectum: palpation reveals a discrete Nodus within the left peripheral zone, spanning roughly 1.5 cm, while right-sided symmetry remains intact. General inspection shows stable vital parameters, absence of palpable lymphadenopathy, and no hepatosplenomegaly.

Patient info: tram driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.80
  uncertainty  +/- 0.07 epistemic (95% band 0.66-0.94); among patients I cannot tell apart the outcome was 0.72 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 23 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.80: PI-RADS 5, PSA 12.0, PSAD 0.411, age 71, DRE Normal -> BIOPSY (borderline). He wrote: "P5 in 71 years old patient with no major comorbidities"
  2. distance 1.85: PI-RADS 5, PSA 17.0, PSAD 0.462, age 61, DRE Normal -> BIOPSY (clear). He wrote: "P5 in 61 year patient"
  3. distance 1.87: PI-RADS 5, PSA 7.6, PSAD 0.236, age 78, DRE Nodus -> BIOPSY (borderline). He wrote: "This is borderline. A P5 but old man and moderately PSA with no symptoms."

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 23 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the need for biopsy in cases with high-risk findings. "A biopsy is recommended for patients with a clinically significant prostate cancer (csPCa) risk, which is often indicated by a high PI-RADS score." The guideline specifies that the decision should be based on the clinical context, including the patient's overall risk profile.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's reliance on the panel variables alone does not account for the PI-RADS 5 finding, which is a key determinant in the cohort criterion. Expert 4's tracing model correctly identifies the importance of the DRE finding, which is a variable that the guideline requires to be considered in the clinical context.

WHAT WE STILL NEED
The guideline requires establishing the csPCa risk. The panel indicates a csPCa predicted probability of 0.84823215. The guideline requires the clinical context to be established, which means the specific details from the radiology report and the PSA trend are needed to fully assess this risk. The prior-biopsy status is known as "None," which is a fact that the guideline makes decisive regarding the need for further investigation.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly points towards biopsy based on the high PI-RADS score and the established csPCa probability, but we must first establish the specific details from the MRI and PSA trend.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the specific finding regarding lesion size and zone from the radiology_report?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values from the psa_trend?
  previous_notes (get_previous_notes) -> What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific finding regarding lesion size and zone from the radiology_report?
  Q2. What is the trend of the serial PSA values from the psa_trend?
  Q3. How does the clinical context, as required by the EAU guideline, fully establish the csPCa risk given the PI-RADS 5 and the PSA trend?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The specific finding regarding lesion size and zone from the radiology_report is: "PI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm."
psa_trend
The trend of the serial PSA values from the psa_trend is: [{"date": "Jan 2023", "val": 3.9}, {"date": "Jul 2023", "val": 5.5}, {"date": "Jan 2024", "val": 7.8}, {"date": "Jul 2024", "val": 11.1}, {"date": "Jan 2025", "val": 15.8}].
previous_notes
The management context regarding prior biopsy status, surveillance protocol, and planned treatment is: "Clinical review on 24 January 2024 documented a PSA level of 15.1 ng/mL, following values of 11.6 ng/mL in early 2023 and a peak reading of 22.1 ng/mL during mid-2023. Persistent elevation alongside a fluctuating trajectory led to urological referral for comprehensive assessment and potential multiparametric MRI scheduling."

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because the panel already indicated a csPCa predicted probability of 0.84823215, which is a key factor for the EAU guideline.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm.
csPCa predicted probability of 0.84823215.
psa trend shows a clear upward trajectory culminating in 15.8 ng/mL.
AGAINST sampling this patient now
previous_notes state the referral was for comprehensive assessment and potential MRI scheduling, not prior biopsy.

WHERE THIS LEANS
The findings strongly support a biopsy due to the high PI-RADS score and the established high csPCa risk probability, aligning with the EAU guideline's emphasis on high-risk findings.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 15.80 ng/mL over 5 points spanning 24 months; velocity +5.88 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 24.1 ng/mL, conformal 95% band 6.9-84.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.76
  uncertainty  +/- 0.07 epistemic (95% band 0.63-0.89), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.80  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.76  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—directly address the moderator's questions. The registrar successfully retrieved the specific finding regarding lesion size and zone, the serial PSA trend, and the management context regarding prior biopsy status.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the findings support the cohort criterion (PI-RADS $\ge 3$) and the clinical context established by the PSA trend and MRI findings.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the specific finding regarding lesion size and zone from the radiology_report? Answered by the registrar: "PI-RADS 5 lesion in the left peripheral zone, base to mid, measuring approximately 18 mm."
Q2. What is the trend of the serial PSA values from the psa_trend? Answered by the registrar: A rising trend culminating in 15.8 ng/mL.
Q3. How does the clinical context, as required by the EAU guideline, fully establish the csPCa risk given the PI-RADS 5 and the PSA trend? This is addressed by the combination of the PI-RADS 5 finding, the csPCa predicted probability of 0.84823215, and the rising PSA trend, which together establish a high-risk profile as required by the EAU guideline.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 finding is paramount as it directly triggers the cohort criterion, which the panel protocol confirms. The rising PSA trend provides temporal evidence of disease progression, and the established csPCa predicted probability provides the necessary clinical context required by the EAU guideline.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the retrieved evidence comprehensively satisfies the criteria outlined in the PANEL-PROTOCOL and the EAU guideline, particularly given the high PI-RADS score and the established risk profile.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the high PI-RADS 5 finding, which is the decisive factor aligning with the cohort criterion. This is supported by the established high csPCa predicted probability of 0.84823215 and the rising PSA trend culminating at 15.8 ng/mL. The evidence converged on biopsy because the retrieved MRI finding and the established risk profile comprehensively satisfy the criteria outlined in the panel protocol and the EAU guideline.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
